Dimensional Fund Advisors LP lessened its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 25.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 121,790 shares of the company's stock after selling 41,835 shares during the quarter. Dimensional Fund Advisors LP's holdings in Sanofi were worth $5,868,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Advisory Services Network LLC increased its holdings in Sanofi by 1.4% in the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company's stock valued at $743,000 after buying an additional 210 shares during the last quarter. Savant Capital LLC lifted its holdings in Sanofi by 2.7% during the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company's stock worth $418,000 after buying an additional 225 shares during the last quarter. Wesbanco Bank Inc. lifted its holdings in Sanofi by 4.9% during the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company's stock worth $239,000 after buying an additional 230 shares during the last quarter. IFG Advisory LLC grew its position in shares of Sanofi by 2.7% in the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company's stock worth $446,000 after acquiring an additional 244 shares in the last quarter. Finally, Cohen Investment Advisors LLC grew its position in shares of Sanofi by 2.9% in the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company's stock worth $457,000 after acquiring an additional 263 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi Stock Up 0.2%
SNY stock opened at $43.56 on Wednesday. The stock has a market cap of $105.61 billion, a PE ratio of 22.81, a price-to-earnings-growth ratio of 1.08 and a beta of 0.35. The firm's 50-day simple moving average is $43.34 and its 200 day simple moving average is $45.01. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21.
Analyst Upgrades and Downgrades
SNY has been the subject of several recent research reports. Weiss Ratings lowered shares of Sanofi from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, August 3rd. Morgan Stanley set a $49.00 price target on shares of Sanofi in a research report on Wednesday, July 8th. BNP Paribas Exane lowered shares of Sanofi from an "outperform" rating to a "neutral" rating and set a $50.00 price target for the company. in a report on Monday, April 20th. Argus raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 27th. Finally, Wall Street Zen lowered shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Sunday. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $49.50.
Read Our Latest Analysis on SNY
About Sanofi
(
Free Report)
Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines.
Further Reading
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
